Imagion Biosystems Limited (ASX: IBX) has lodged “Appendix 3B: New issue announcement, application for quotation of additional securities and agreement” with the Australian Securities Exchange.View “Appendix 3B: New issue announcement”
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce